Name : Biotinylated Human FcRH5/FcRL5 Protein (Primary Amine Labeling)
Product Source :
Recombinant Biotinylated Human FcRH5/FcRL5 Protein (Primary Amine Labeling) is expressed from HEK293 with His tag at the C-Terminus. It contains Gln16-Gly851.[Accession | AAK93971]
Molecular Weight :
The protein has a predicted MW of 92.38 kDa. Due to glycosylation, the protein migrates to 100-120 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 90% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS, 100mM Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Biotinylated Human FcRH5 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Biotinylated Human FcRH5 is greater than 90% as determined by SEC-HPLC. ELISA Data Immobilized Anti-FcRH5 Antibody, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human FcRH5, His Tag with the EC50 of 46.0ng/ml determined by ELISA.
Background :
FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
Synonyms :
FcR-like protein 5; FcRH5; FcRL5; BXMAS1; BXMAS1MGC119592; CD307; CD307e; DKFZp667E2019; DKFZp667F216; FCRH5MGC119593; FLJ00333; FLJ00397; IFGP5; IRTA2
References & Citations :
(1)Elkins K, Zheng B, Go M, et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. Mol Cancer Ther. 2012;11(10):2222-2232. doi:10.1158/1535-7163.MCT-12-0087.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations: IFN-gamma R2 Protein SCF Protein I-TAC/CXCL11 IFN-lambda 2/IL-28A